NIH Multi-Year Funded Grants: How the Lump-Sum Policy Reshapes R01 Strategy in 2026

What Changed: Annual Increments vs. Lump-Sum MYF Awards

For most of NIH's history, a multi-year R01 worked like this: the agency awarded Year 1 funding, and Years 2 through 4 or 5 showed up as non-competing renewals. From a federal budget accounting perspective, only the current year's increment counted as an obligation. That gave institutes flexibility. They could commit to a new R01 by funding Year 1 and manage the out-year costs across future appropriations. In a typical year, this meant they could launch more new projects than their single-year budget would appear to support.

Multi-Year Funded (MYF) awards change that accounting structure. Under MYF, NIH commits the full budget for the entire project period in Year 1. If an R01 runs four years, the entire four-year total is obligated upfront. The science doesn't change, but the fiscal footprint per new award roughly quadruples relative to the old annual-increment model. The practical consequence is that the same appropriation supports far fewer new awards per year. At the National Cancer Institute — the most prominently reported example — the fraction of applicants who received funding reportedly fell from roughly one in ten to approximately one in twenty-five after the MYF transition took hold in 2025.

Those figures come from reporting by Science and have not been independently verified by direct NIH data releases at the time of writing. The direction of the trend is confirmed by NIH's own FY 2025 extramural numbers. Individual study sections, mechanisms, and institutes will vary, and a single year's data shouldn't be read as a permanent new baseline — but it would be a mistake to dismiss the magnitude of the shift.

What the 2025 Numbers Actually Show

NIH's FY 2025 extramural data show a clear downward step. The total number of investigators winning R01-equivalent grants dropped from around 7,720 in FY 2024 to roughly 5,885 in FY 2025, a decline of about 1,800 investigators in a single year. The funding rate for early-stage investigators fell from roughly 26% in FY 2024 to about 19% in FY 2025, according to Science reporting on NIH RePORT data. These are not normal year-to-year fluctuations. They reflect a structural change in how many new awards the NIH portfolio can absorb in a given fiscal year under current accounting rules.

The 2026 appropriations bill did not reverse the MYF framework. It capped multiyear funding at FY 2025 levels, which means the number of new R01-equivalent awards in FY 2026 is likely to remain near the compressed 2025 baseline. Whether that cap is maintained, loosened, or tightened in FY 2027 depends on budget negotiations that are unresolved at this writing. The Senate has been actively debating the multiyear funding limit since early 2026, and the outcome isn't predictable from where we sit.

Why This Is Structurally Different From a Budget Cut

Standard NIH budget reductions lower success rates by shrinking the dollar pool. The MYF shift lowers them by changing the accounting horizon, even with the same or a larger total appropriation. That distinction matters strategically, because the recovery dynamics are different.

In a budget-cut environment, higher appropriations translate fairly directly into more awards. In the MYF environment, even restored funding doesn't immediately free up new-award capacity. The out-year commitments from grants awarded in 2024 and 2025 are already occupying future budget space. The portfolio has to age out some of those commitments before new-award room reopens. That is a slower recovery dynamic than most researchers have planned around before, and it explains why predictions of a quick bounce-back haven't materialized.

A second structural difference is that Program Officers have less near-term visibility than usual. In a traditional payline environment, a PO could tell you with reasonable confidence whether your score was likely to fund in the current cycle. Without paylines and with MYF constraints on new-award capacity, a PO who says they genuinely don't know what will happen with your score in the next quarter is probably being honest, not evasive. Go into post-score conversations with specific questions about portfolio priorities rather than expecting a firm funding forecast.

How the Environment Changes the New-Applicant Calculus

If you're preparing a first R01 — or a fresh submission after a rejection — the compressed success-rate environment sharpens the cost of strategic mistakes that were always worth avoiding.

Mechanism choice carries more strategic weight than it did a few years ago. R21, R03, and certain cooperative mechanism types draw on different budget pools and aren't subject to MYF accounting in the same way an R01 is. If your research question genuinely fits a two-year R21 scope, the current funding environment is a real data point in favor of that choice. That said, don't stretch the science to fit a mechanism it doesn't match. A borderline R21 that reviewers read as an R01-in-disguise will score worse than a well-scoped R01 in most study sections, and a worse score has higher stakes now than it did when paylines were more predictable.

The realistic score threshold for a serious funding conversation has also shifted. Without institute paylines as anchors, and with compressed new-award capacity, the score you need for a genuine post-score discussion about near-term funding is tighter than it was in 2023. Use that knowledge to calibrate your resubmission decision — not to discourage submission, but to raise the bar you hold yourself to before you click submit the first time.

One practical step before finalizing your Specific Aims: use NIH RePORTER to look at what types of projects your target study section actually funded in the last two cycles. Not just the score distribution — but which scientific areas received awards, for which mechanism types, and at what budget levels. That pattern is imperfect information, but it's better than going in blind about whether your framing sits in an actively funded niche or a saturated one.

What Renewal Applicants Should Know

If you're holding an R01 approaching a competitive renewal, your situation is operationally different from a new applicant but not entirely separate from the MYF environment. The competitive renewal process itself is unchanged: write a Type 2 application, undergo peer review, receive a score. What has changed is the portfolio context your renewal lives in. Portfolio managers are balancing existing MYF commitments alongside new applications, and there is no public rule for how that affects renewal favorability relative to new awards in any given institute or cycle. It is worth asking your Program Officer explicitly how renewals have been faring in your study section over the last two cycles — they may know patterns that aren't visible from RePORTER alone.

One operational change worth confirming: if your current grant was transitioned to multi-year funded status, your progress reporting requirements changed. Instead of annual Research Performance Progress Reports (RPPRs), you submit a single Multi-Year Funded Progress Report covering the full project period before competitive renewal. NIH has guidance on MYF progress reports at grants.nih.gov, and ASSIST handles the submission. If your Grants Management Specialist hasn't reached out about this, confirm which reporting model applies to your award before your renewal submission window opens — the last thing you want is a compliance question tangled up in a renewal timeline.

Positioning a Proposal When the Odds Are Tighter

The fundamentals of a strong R01 haven't changed. Reviewers still reward a problem statement the broader panel recognizes as important, a central hypothesis the proposed work can actually test, and a team with the specific expertise the project requires. What the compressed environment changes is the marginal cost of getting these elements wrong.

Frequently Asked Questions